{"id":1245,"date":"2020-10-22T10:54:05","date_gmt":"2020-10-22T08:54:05","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=1245"},"modified":"2020-10-22T10:54:05","modified_gmt":"2020-10-22T08:54:05","slug":"interim-report-july-1-september-30-2020","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/","title":{"rendered":"Interim report July 1 – September 30, 2020"},"content":{"rendered":"
\n
\n
\n

By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203.<\/p>\n

First Quarter Summary (July – September 2020)<\/strong><\/p>\n

\u2022 Net sales amounted to MSEK 0.0 (0.0)
\n\u2022 Operating profit\/loss amounted to MSEK -1.5 (-2.0)
\n\u2022 Earnings per share * SEK -0.10 (-0.13)
\n\u2022 Cash and cash equivalents at the end of the period amounted to MSEK 5.5 (8.2)<\/p>\n

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 14,920,478. For the comparison period, the average number of shares was 14,887,678. Amounts in brackets refer to the corresponding period last year.<\/p>\n

CEO’s comment<\/strong><\/p>\n

In June 2020, DexTech’s Phase IIb study of the drug candidate OsteoDex for the treatment of advanced prostate cancer, skeletal metastatic castration-resistant prostate cancer (mCRPC), was completed, with 2-year follow-up results obtained from the last patients. The follow-up results from the study were very positive and show that OsteoDex treatment can slow down the disease. The results show significantly longer survival for patients who responded to the treatment. The treatment was very well tolerated (no serious side effects) and good disease-inhibiting effect was seen even in the lowest doses. Slowing and regression of the disease was also seen in patients where the disease has progressed after treatment with several of the other available drugs for castration-resistant prostate cancer.
\nNone of the modern drugs is curative in castration-resistant prostate cancer and there is therefore a great need (unmet need) for new potent and well-tolerated drugs. OsteoDex has a clear potential to meet this need.
\nDexTech is working towards the company’s primary goal, to enter into an agreement with a licensee for the company’s drug candidate OsteoDex for the treatment of skeletal metastases in advanced prostate cancer (mCRPC) before the end of 2020. A majority of our stakeholders had expressed a desire for new contact when the follow-up results were completed, which can be largely understood as the result should give an indication of whether the OsteoDex treatment affects survival, which is the ultimate intention of CRPC treatment. Dialogue is ongoing, including with new stakeholders.
\nThe ongoing Corona pandemic has, of course, affected the out-licensing work to the extent that contacts with stakeholders are somewhat slower and exclude physical meetings that are replaced by telephone \/ video meetings. Herein lies an educational challenge, i.e. to be able to explain and shed light on the clinical status of CRPC and OsteoDex place in the treatment, and, not least, the great potential of our platform technology. Here we have great benefit from our clinical expert.<\/p>\n

Anders R Holmberg CEO<\/p>\n<\/div>\n

See the entire report: Dextech – Interim report Juli-September 2020<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July – September 2020) \u2022 Net sales amounted to MSEK 0.0 (0.0) \u2022 Operating […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1245","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"\nInterim report July 1 - September 30, 2020 | DexTech<\/title>\n<meta name=\"description\" content=\"By "Company" or "DexTech" is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July - September 2020) \u2022 Net sales\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim report July 1 - September 30, 2020 | DexTech\" \/>\n<meta property=\"og:description\" content=\"By "Company" or "DexTech" is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July - September 2020) \u2022 Net sales\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-22T08:54:05+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/\",\"url\":\"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/\",\"name\":\"Interim report July 1 - September 30, 2020 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2020-10-22T08:54:05+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"By \\\"Company\\\" or \\\"DexTech\\\" is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July - September 2020) \u2022 Net sales\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim report July 1 – September 30, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim report July 1 - September 30, 2020 | DexTech","description":"By \"Company\" or \"DexTech\" is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July - September 2020) \u2022 Net sales","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/","og_locale":"en_US","og_type":"article","og_title":"Interim report July 1 - September 30, 2020 | DexTech","og_description":"By \"Company\" or \"DexTech\" is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July - September 2020) \u2022 Net sales","og_url":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/","og_site_name":"DexTech","article_published_time":"2020-10-22T08:54:05+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/","url":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/","name":"Interim report July 1 - September 30, 2020 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2020-10-22T08:54:05+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"By \"Company\" or \"DexTech\" is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July - September 2020) \u2022 Net sales","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Interim report July 1 – September 30, 2020"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=1245"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1245\/revisions"}],"predecessor-version":[{"id":1248,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1245\/revisions\/1248"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=1245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=1245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=1245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}